Prestige Consumer Healthcare Inc. (NYSE:PBH) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) have earned an average rating of “Hold” from the six analysts that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $70.75.

A number of brokerages have recently commented on PBH. Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Zacks Research downgraded Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research report on Monday, May 18th. Finally, Weiss Ratings lowered Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th.

Prestige Consumer Healthcare Stock Performance

Prestige Consumer Healthcare stock traded up $1.16 during mid-day trading on Tuesday, reaching $50.02. The company had a trading volume of 161,796 shares, compared to its average volume of 570,034. The company has a 50 day moving average of $49.19 and a 200-day moving average of $58.16. Prestige Consumer Healthcare has a 52 week low of $42.62 and a 52 week high of $79.58. The company has a quick ratio of 2.25, a current ratio of 3.57 and a debt-to-equity ratio of 0.54. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of 12.81, a PEG ratio of 1.59 and a beta of 0.35.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.39 by ($0.16). Prestige Consumer Healthcare had a return on equity of 11.54% and a net margin of 17.48%.The business had revenue of $281.62 million during the quarter, compared to analyst estimates of $293.64 million. During the same period last year, the company earned $1.32 EPS. The business’s revenue for the quarter was down 5.0% on a year-over-year basis. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. On average, sell-side analysts expect that Prestige Consumer Healthcare will post 4.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, VP Jeffrey Zerillo sold 1,207 shares of the company’s stock in a transaction that occurred on Tuesday, May 5th. The stock was sold at an average price of $54.99, for a total value of $66,372.93. Following the transaction, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. This represents a 2.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.50% of the stock is currently owned by company insiders.

Institutional Trading of Prestige Consumer Healthcare

Large investors have recently added to or reduced their stakes in the stock. Versant Capital Management Inc raised its holdings in Prestige Consumer Healthcare by 47.9% during the 2nd quarter. Versant Capital Management Inc now owns 726 shares of the company’s stock valued at $34,000 after acquiring an additional 235 shares during the period. Pacer Advisors Inc. raised its stake in shares of Prestige Consumer Healthcare by 116.5% during the 1st quarter. Pacer Advisors Inc. now owns 2,866 shares of the company’s stock valued at $170,000 after purchasing an additional 1,542 shares during the period. Empowered Funds LLC purchased a new stake in Prestige Consumer Healthcare during the 1st quarter worth about $236,000. Amundi boosted its stake in Prestige Consumer Healthcare by 18.1% in the 1st quarter. Amundi now owns 9,252 shares of the company’s stock worth $548,000 after purchasing an additional 1,421 shares during the period. Finally, EverSource Wealth Advisors LLC increased its position in shares of Prestige Consumer Healthcare by 19.4% during the first quarter. EverSource Wealth Advisors LLC now owns 1,531 shares of the company’s stock valued at $91,000 after buying an additional 249 shares during the period. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).